how to give semaglutide injection with syringe Injecting How to Inject Your Semaglutide/Tirzepatide

Status: Early-phase human trials Not commercially available SC injection (research settings) Caveat: Strong mechanistic case

PMID 23631642

Adjustments are made when necessary

Gastrointestinal adverse events Very common (10% or more): Diarrhea (35%), abdominal pain (21%), vomiting (21%), nausea (12%) Common (1% to 10%): Constipation, dyspepsia, gastrointestinal disorder, melena Very rare (less than 0.01%): Abdominal cramps [Ref] Nervous system Very common (10% or more): Headache (37%), dizziness (18%), paresthesia (12%) Common (1% to 10%): Hypertonia, vertigo, taste perversion Frequency not reported : Seizures (with or without pre-existing seizure activity), increase in seizure frequency and/or severity [Ref] Metabolic Very common (10% or more): Hypercalcemia (15%), hypervolemia (12%) Common (1% to 10%): Anorexia, hyperkalemia [Ref] There are reports from clinical trials of significant hypertriglyceridemia associated with high doses of levocarnitine (3 g/day) given to uremic dialysis patients

B., Chan, G